17 results about "Gastrointestinal disorder" patented technology

A method for treating conditions of the gastrointestinal tract of a subject using a vibrating ingestible capsule ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject. The conditions may include a sensation of gastric bloating, a sensation of straining during defecating, diarrhea and / or gastroparesis. The method is further suitable for reducing Bristol stool scores of fecal matter of the subject and for increasing a Bristol stool score of fecal matter of the subject.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Embodiments of the present disclosure relate to the technical field of medical data processing, and specifically to a nutritional preparation medication information processing method, device, equipment and medium. The main steps of the foregoing method include: in response to an audit request for a medication prescription, retrieving and obtaining clinical diagnosis data corresponding to the medication prescription, extracting a disease keyword from the clinical diagnosis data, matching and analyzing the disease keyword with preset parenteral nutrition indication information to obtain a matching result, when the matching result indicates a matching success, auditing the medication prescription according to a first medication standard, and when the matching result indicates a matching failure, determining a second medication standard according to a nutritional risk score, gastrointestinal disorder information and a preset decision matrix, and auditing the medication prescription according to the second medication standard. The foregoing method can improve the efficiency of prescription auditing, improve the accuracy and rationality of the nutritional preparation medication prescription audit result, and reduce the medication risk of the nutritional preparation medication prescription.

Provided herein are pharmaceutical compositions comprising a bacterial population. The bacterial population comprises one bacterial strains or at least two bacterial strains. Such pharmaceutical compositions can be administered to a subject for prevention and / or treatment of dysbiosis and dysbiosis associated conditions and diseases, such as infant gastrointestinal diseases.

The present application discloses diagnostic methods and kits for detecting disease activity in a subject having an inflammatory bowel disease, such as Crohn's disease. Methods of treating endoscopically active gastrointestinal disease, as well as methods of determining effectiveness of a treatment for endoscopically active gastrointestinal disease in a subject, are also disclosed.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and / or dysbiosis.

Provided herein are biomarkers that are useful in various aspects of treating and preventing complications and side effects associated with a disease or disorder, such as those associated with immune suppression, disruption of the gastrointestinal microbiome, infections (e.g., bloodstream infections), and / or GvHD, for example, in HSCT subjects. In some aspects, the biomarkers provided herein can be used in identifying a subject who is responding to a bacterial composition and / or subjects that are suitable for a treatment with a bacterial composition.

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

This article provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in cells or subjects, and in some cases, reducing the amount of SCN2A protein in cells or subjects. Such compounds, methods, and pharmaceutical compositions can be used to improve at least one symptom or marker of a disease or disorder associated with voltage-gated sodium channel proteins, such as, for example, developmental and epileptic encephalopathy, intellectual disability, or autism spectrum disorder. Such symptoms and markers include, but are not limited to, seizures, hypotonia, sensory integration dysfunction, delayed and impaired motor development, intellectual and cognitive impairment, motor and balance impairment, visual impairment, language and speech delay, gastrointestinal disorders, delayed neurodevelopment, sleep problems, and sudden unexpected death in epilepsy.

The present invention describes the synthesis and use of nanoparticles derived from the leaves of Globularia alypum, a medicinal plant native to the Gafsa region, known for its therapeutic properties. This invention makes it possible to utilize the active compounds of this plant in nanoparticle form in order to improve their efficacy and bioavailability for the treatment of gastrointestinal disorders, particularly constipation. The aqueous extract of Glohularia alypum leaves contains bioactive compounds that act on the digestive system, thus facilitating intestinal transit and reducing constipation. Simultaneously, the use of AgNG allows for better absorption of the active compounds by the body. The preparation process for AgNGs involves mixing the aqueous extract of Glohularia alypum with an Ag NO3 solution and incubating for 15 minutes at 60°C.

Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.

Provided herein are metabolites and methods of using the metabolites for diagnosing and treating Autism Spectrum Disorder (ASD) in a subject with a gastrointestinal problem, for determining a personalized treatment protocol for the subject, and for monitoring the therapeutic effect of an ASD treatment protocol in the subject being treated with the ASD treatment protocol.

In particular, this invention refers to a composition comprising a probiotic combination comprising: a) at least one strain of the genus Lactobacillus selected from the species Lactobacillus plantarum; and c) at least one strain belonging to the genus Bifidobacterium selected from the species Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis; wherein said composition is for use in a method for the prevention and / or treatment of chronic inflammatory bowel disease (Inflammatory Bowel Disease IBD).

Provided herein are peptide analogs of gastrin releasing peptide (GRP), corresponding pharmaceutical compositions, and methods of using such peptide analogs of GRP in the treatment of a disease or disorder, such as gastrointestinal disease or obesity.

Provided herein are biomarkers that are useful in various aspects of treating and preventing complications and side effects associated with a disease or disorder, such as those associated with immune suppression, disruption of the gastrointestinal microbiome, infections (e.g., bloodstream infections), and / or GvHD, for example, in HSCT subjects. In some aspects, the biomarkers provided herein can be used in identifying a subject who is responding to a bacterial composition and / or subjects that are suitable for a treatment with a bacterial composition.

To provide a method for treating gastrointestinal disorders using a modified WNT agonist and a modulator of the WNT signaling pathway. [Solution] In one embodiment, the present disclosure includes an engineered WNT agonist comprising (a) one or more binding domains that bind to one or more FZDs; and (b) one or more binding domains that bind to LRP5, LRP6, or both LRP5 and LRP6, wherein the polypeptide sequence has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1 to 18, or a polypeptide sequence disclosed in any one of SEQ ID NOs: 1 to 25, Figure 2, Figure 6, Table 1, or Table 3, or a functional fragment or variant thereof, for example, its binding fragment, for example, a VHH domain, a heavy chain variable domain, or a light chain variable domain.